A major trend in healthcare is Personalized Medicine. This is the idea where the unique genetic characteristics of a patient are used to pick the drugs that will best match the patient’s profile. We are very interested and active in this area, because our technology has been designed to be able to use a patient profile to screen for and systematically match drugs to that profile.

Initially, we are focusing our proof of concept work in Pancreatic Cancer. Our meta-review and gap analysis of the space identified at least 24 molecular targets associated with the disease. However, current chemotherapy – which includes 5-FU, erlotinib and gemcitabine – at best targets 3-9 of the 24 targets.

Using this knowledge, we screened for drugs that can inhibit different targets to the ones of current chemotherapy and we have identified a number of exciting opportunities. Using patient genotyping, we believe that our new drug combinations have the potential to be more tailored and personalized for each patient.

Beyond pancreatic cancer, our approach of matching the molecular epidemiology of a patient and disease to possible drugs is applicable to a number of complex diseases, such as Parkinson’s, Alzheimer’s, certain auto-immune disorders, certain infectious diseases and others and we are exploring those options.

If you are working in Personalized Medicine programs or are interested in one of ours, please contact us.